Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on BioNTech SE yesterday and set a price target of $134.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Tazeen Ahmad has given his Buy rating due to a combination of factors, primarily focusing on the promising data from BioNTech’s global Phase 2 trial for pumitamig in treating triple-negative breast cancer (TNBC). The trial results showed a compelling objective response rate and progression-free survival, which align with previous data from trials conducted in China. This consistency suggests a strong potential for pumitamig to offer a differentiated clinical profile compared to the standard of care, particularly in a global context.
Furthermore, the safety profile of pumitamig appears manageable, with a relatively low incidence of severe treatment-related adverse events. This, coupled with the ongoing Phase 3 trial and several other promising oncology catalysts anticipated in 2026, underpins the long-term value potential of BioNTech’s pipeline. Ahmad’s analysis reflects confidence in BioNTech’s strategic positioning and its ability to meet high unmet medical needs, justifying the Buy rating and a price objective of $134.
In another report released yesterday, Citi also maintained a Buy rating on the stock with a $145.00 price target.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BNTX in relation to earlier this year.